Home » Stocks » SRRK

Scholar Rock Holding Corporation (SRRK)

Stock Price: $51.01 USD -5.91 (-10.38%)
Updated Jan 20, 2021 2:37 PM EST - Market open
Market Cap 1.91B
Revenue (ttm) 19.54M
Net Income (ttm) -71.49M
Shares Out 29.78M
EPS (ttm) -2.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $51.01
Previous Close $56.92
Change ($) -5.91
Change (%) -10.38%
Day's Open 56.17
Day's Range 50.01 - 56.89
Day's Volume 186,451
52-Week Range 9.63 - 58.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

The Motley Fool - 2 months ago

Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.

Other stocks mentioned: REPL
Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein gro...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein gro...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein gro...

The Motley Fool - 2 months ago

Investors are fired up about the company's interim phase 2 results for an experimental spinal muscular atrophy drug.

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

Seeking Alpha - 5 months ago

Scholar Rock Holding Corp. (SRRK) CEO Tony Kingsley on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -22.64% and -40.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies a...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

Business Wire - 5 months ago

CAMBRIDGE, Mass--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fu...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

Zacks Investment Research - 8 months ago

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -480.00% and -74.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies...

Zacks Investment Research - 8 months ago

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Scholar Rock has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 9 months ago

Is (SRRK) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 10 months ago

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 31.58% and 38.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies...

GlobeNewsWire - 1 year ago

-  Completed enrollment of TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases i...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein grow...

Zacks Investment Research - 1 year ago

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -77.42% and -62.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what l...

GuruFocus - 1 year ago

Falling knives are stocks whose share price has fallen more than 59% over the past year, drawing interest from investors as these securities can deliver huge rewards if they rebound.

Other stocks mentioned: FLDM
GlobeNewsWire - 1 year ago

Preclinical and Phase 1 data support the evaluation of SRK-015 in ongoing Phase 2 trial for the treatment of patients with Type 2 and Type 3 spinal muscular trophy Preclinical and Phase 1 data...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Scholar Rock Holding.

GlobeNewsWire - 1 year ago

Highly experienced physician-scientist and drug developer to lead SRK-015 latent myostatin program Highly experienced physician-scientist and drug developer to lead SRK-015 latent myostatin pr...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical stage biopharmaceutical company, announced today that its Chief Financial Offi...

The Motley Fool - 1 year ago

Find out why these stocks missed the rally.

Other stocks mentioned: CCL, SCS
The Motley Fool - 1 year ago

The good news? The cause of the drop should be a temporary issue.

About SRRK

Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, a novel inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to c... [Read more...]

Industry
Biotechnology
IPO Date
May 24, 2018
CEO
Nagesh Mahanthappa
Employees
93
Stock Exchange
NASDAQ
Ticker Symbol
SRRK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is 55.25, which is an increase of 8.31% from the latest price.

Price Target
$55.25
(8.31% upside)
Analyst Consensus: Buy